Odyssey Therapeutics (ODTX), which is developing treatments for inflammatory bowel disease, has filed for a $100M initial ...

The company said Friday it develops medicines designed to precisely target disease pathology with an initial emphasis on the innate immune system. Odyssey said its most advanced programs include ...